Inhibition of Complement and CD14 Attenuates theEscherichia coli-Induced Inflammatory Response in Porcine Whole Blood
Open Access
- 1 February 2009
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 77 (2), 725-732
- https://doi.org/10.1128/iai.01305-08
Abstract
The innate immune response is a double-edged sword in systemic inflammation and sepsis. Uncontrolled or inappropriate activation can damage and be lethal to the host. Several studies have investigated inhibition of downstream mediators, including tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β). Emerging evidence indicates that upstream inhibition is a better therapeutic approach for attenuating damaging immune activation. Therefore, we investigated inhibition of two central innate immune pathways, those of complement and CD14/Toll-like receptor 4 (TLR4)/myeloid differentiation protein 2 (MD-2), in a porcine in vitro model ofEscherichia coli-induced inflammation. Porcine whole blood anticoagulated with lepuridin, which did not interfere with the complement system, was incubated withE. colilipopolysaccharide (LPS) or whole bacteria. Inhibitors of complement and CD14 and thus the LPS CD14/TLR4/MD-2 receptor complex were tested to investigate the effect on the inflammatory response. A broad range of inflammatory readouts were used to monitor the effect. Anti-CD14 was found to saturate the CD14 molecule on granulocytes and completely inhibited LPS-induced proinflammatory cytokines in a dose-dependent manner. Anti-CD14 significantly reduced the levels of theE. coli-induced proinflammatory cytokines TNF-α and IL-1β, but not IL-8, in a dose-dependent manner. No effect on bacterial clearance was seen. Vaccinia complement control protein and smallpox inhibitor of complement enzymes, twoOrthopoxvirus-encoded complement inhibitors, completely inhibited complement activation. Furthermore, these agents almost completely inhibited the expression of wCD11R3, which is associated with CD18 as a β2 integrin, on porcine granulocytes and decreased IL-8 levels significantly in a dose-dependent manner. As expected, complement inhibition reduced bacterial clearance. We conclude that inhibition of complement and CD14 attenuatesE. coli-induced inflammation and might be used as a therapeutic regimen in gram-negative sepsis along with appropriate treatment with antibiotics.Keywords
This publication has 52 references indexed in Scilit:
- Identification of Hot Spots in the Variola Virus Complement Inhibitor (SPICE) for Human Complement RegulationJournal of Virology, 2008
- Locally Produced Complement Fragments C5a and C3a Provide Both Costimulatory and Survival Signals to Naive CD4+ T CellsImmunity, 2008
- Regulation of Toll-like receptor–mediated inflammatory response by complement in vivoBlood, 2007
- Complement Receptor 3 and Toll-Like Receptor 4 Act Sequentially in Uptake and Intracellular Killing of UnopsonizedSalmonella entericaSerovar Typhimurium by Human NeutrophilsInfection and Immunity, 2007
- Candidate inhibitors of porcine complementMolecular Immunology, 2007
- Pathogen Recognition and Innate ImmunityCell, 2006
- Vaccinia Virus Complement Control Protein Ameliorates Collagen-Induced Arthritic MiceAnnals of the New York Academy of Sciences, 2005
- Vaccinia Virus Complement Control Protein Diminishes Formation of Atherosclerotic Lesions: Complement Is Centrally Involved in Atherosclerotic DiseaseAnnals of the New York Academy of Sciences, 2005
- Workshop studies on monoclonal antibodies in the myeloid panel with CD11 specificityVeterinary Immunology and Immunopathology, 2001
- RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate ProteoglycansCell, 2001